Recognizing that the prevalence of both obesity and type 2 diabetes mellitus (T2DM) are on the rise in the United States, Peter Salgo, MD, explains how the 2 diseases march hand-in-hand and have a major impact on US healthcare spending.
Dr Salgo explains that the prevalence of T2DM increases with weight and states that the annual costs associated with T2DM are approximately $245 billion. The cost burden of T2DM is reflected in both direct expenditures and costs associated with lost productivity and absenteeism.
Kari Uusinarkaus, MD, FAAFP, FNLA, and Yehuda Handelsman, MD, FACP, FACE, FNLA, discuss how the trends are noticeable in each of their respective US states.
Jeffrey D. Dunn, PharmD, MBA, describes how the diabetes and obesity epidemics, combined with life expectancies, an aging population, comorbidities, and drug prices, exert a substantial burden on society.
Maria Lopes, MD, MS, explains how educational efforts and resources that help support patients can help empower patients to take responsibility for their health. Dr Handelsman suggests that a nationwide government-directed intervention is necessary to reverse the trend of increasing obesity prevalence.
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
USPSTF Lowers Age for Biennial Mammograms to 40, Citing Early Detection Benefit
April 30th 2024The USPSTF lowered the recommended starting age for mammograms from 50 to 40 years, citing moderate benefits for early detection in this age group. Disparities persist, especially for Black women, highlighting the need for improved access to health care and social support.
Read More
Makers of medical tests will have about 4 years to show the FDA that their new offerings deliver accurate results; after previously decreasing for 27 years, US tuberculosis (TB) cases increased every year since 2020; a US district judge rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to the Medicare drug price negotiation program.
Read More